BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Medtech firm Translumina bolsters German presence with acquisition of Lamed GmbH

07 June 2023 | News

To excel in interventional cardiology, peripheral vascular, and structural heart disease segments



New Delhi-based Translumina, a global leader in interventional cardiovascular medical devices with manufacturing presence in Germany and India, has announced the acquisition of Munich-based Lamed GmbH. With this acquisition, Translumina has taken a step further towards its stated goal of providing a comprehensive cardiovascular portfolio at scale across key markets globally.

Established in 1989, Lamed is a leading market access platform of vascular and cardiovascular products. It covers 1,000+ hospitals through its GPO network in Germany, which is the largest interventional cardiology market in Europe; the company exclusively distributes a portfolio of differentiated products for a marquee international supplier base. Lamed's seasoned senior management team brings 30+ years of experience and deeply entrenched ecosystem relationships. Translumina intends to leverage the platform to introduce a basket of owned and partnered products in the German market.

"This acquisition is of strategic importance and gives us significant access in vascular and cardiovascular markets in Germany , which is one of the largest in Europe. The synergy of our unique technologies and market penetration of Lamed shall create a formidable business opportunity for us," said Gurmit Singh Chugh who along with Punita Sharma founded Translumina in 2010.